Astellas Pharma has entered into a definitive agreement to buy US-based biopharmaceutical company IVERIC bio, in a deal valued at nearly $5.9bn.

Under the deal terms, the company, through Astellas US Holding’s wholly owned subsidiary Berry Merger Sub, will acquire all the outstanding Iveric Bio shares for $40.00 in cash for each share.

Both the companies’ Boards of Directors have unanimously approved the deal.

Iveric Bio is focused on the discovery as well as development of new therapies for retinal diseases with significant unmet medical needs.

In February this year, the US Food and Drug Administration (FDA) accepted for filing the company’s new drug application (NDA) for Avacincaptad Pegol (ACP) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Astellas expects that the deal will advance its primary focus on “Blindness & Regeneration”.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, the transaction will offer a foundation of ophthalmology focused capabilities, including expansive experts’ network in the ophthalmology field, a multi-faceted commercial team, and the infrastructure and experience to drive the combined ophthalmology business further.

Astellas president and CEO Naoki Okamura said: “We are pleased to reach an agreement with Iveric Bio, a company with exceptional expertise in the R&D of innovative therapeutics in the ophthalmology field.

“Iveric Bio has promising programmes including Avacincaptad Pegol (ACP), an important programme for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD), and capabilities across the entire value chain in the ophthalmology field.

“We believe that this acquisition will enable us to deliver greater VALUE to patients with ocular diseases at high risk of blindness.”

The transaction, which is subject to approval from Iveric Bio’s stockholders and other customary closing conditions, is anticipated to be concluded in the second quarter of Astellas’ fiscal year 2023.

Upon completion of the acquisition, Iveric Bio will become an indirectly wholly owned Astellas’ subsidiary.